References
Key articles
Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024 Jan 2;83(1):15-29.Full text Abstract
Sammaritano LR, Askanase A, Bermas BL, et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Rheumatol. 2025 Sep;77(9):1115-35.Full text Abstract
Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024 Jan;105(1s):S1-69.Full text Abstract
Parodis I, Girard-Guyonvarc'h C, Arnaud L, et al. EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. Ann Rheum Dis. 2024 May 15;83(6):720-9.Full text Abstract
Reference articles
1. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019 Sep;71(9):1400-12.Full text Abstract
2. Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018 Apr;93(4):789-96.Full text Abstract
3. Rees F, Doherty M, Grainge MJ, et al. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017 Nov 1;56(11):1945-61.Full text Abstract
4. Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018 Mar;30(2):144-50.Full text Abstract
5. Fatoye F, Gebrye T, Mbada C. Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis. Rheumatol Int. 2022 Dec;42(12):2097-107.Full text Abstract
6. Rees F, Doherty M, Grainge M, et al. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis. 2016 Jan;75(1):136-41.Full text Abstract
7. Mitchet CJ Jr, McKenna CH, Elveback LR, et al. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1985 Feb;60(2):105-13. Abstract
8. Flower C, Hennis AJ, Hambleton IR, et al. Systemic lupus erythematosus in an African Caribbean population: incidence, clinical manifestations, and survival in the Barbados National Lupus Registry. Arthritis Care Res (Hoboken). 2012 Aug;64(8):1151-8.Full text Abstract
9. Izmirly PM, Parton H, Wang L, et al. Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol. 2021 Jun;73(6):991-6. Abstract
10. Morand EF, Fernandez-Ruiz R, Blazer A, et al. Advances in the management of systemic lupus erythematosus. BMJ. 2023 Oct 26;383:e073980.Full text Abstract
11. Masi AT, Kaslow RA. Sex effects in SLE: a clue to pathogenesis. Arthritis Rheum. 1978 May;21(4):480-4. Abstract
12. Costenbader KH, Feskanich D, Stampfer MJ, et al. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 2007 Apr;56(4):1251-62.Full text Abstract
13. Lawrence JS, Martins CL, Drake GL. A family survey of lupus erythematosus. 1. Heritability. J Rheumatol. 1987 Oct;14(5):913-21. Abstract
14. Deapen D, Escalante A, Weinrib L, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992 Mar;35(3):311-8. Abstract
15. Kuo CF, Grainge MJ, Valdes AM, et al. Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families. JAMA Intern Med. 2015 Sep;175(9):1518-26.Full text Abstract
16. Teruel M, Alarcón-Riquelme ME. The genetic basis of systemic lupus erythematosus: what are the risk factors and what have we learned. J Autoimmun. 2016 Nov;74:161-75. Abstract
17. Soni C, Reizis B. DNA as a self-antigen: nature and regulation. Curr Opin Immunol. 2018 Dec;55:31-7.Full text Abstract
18. Fan Y, Li LH, Pan HF, et al. Association of ITGAM polymorphism with systemic lupus erythematosus: a meta-analysis. J Eur Acad Dermatol Venereol. 2011 Mar;25(3):271-5. Abstract
19. Wang JM, Huang AF, Yuan ZC, et al. Association of IRF5 rs2004640 polymorphism and systemic lupus erythematosus: a meta-analysis. Int J Rheum Dis. 2019 Sep;22(9):1598-606. Abstract
20. Goropevšek A, Holcar M, Avčin T. The role of STAT signaling pathways in the pathogenesis of systemic lupus erythematosus. Clin Rev Allergy Immunol. 2017 Apr;52(2):164-81. Abstract
21. Kozyrev SV, Abelson AK, Wojcik J, et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet. 2008 Feb;40(2):211-6. Abstract
22. Lee YH, Bae SC. Association between the functional ITGAM rs1143679 G/A polymorphism and systemic lupus erythematosus/lupus nephritis or rheumatoid arthritis: an update meta-analysis. Rheumatol Int. 2015 May;35(5):815-23. Abstract
23. Kyogoku C, Langefeld CD, Ortmann WA, et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet. 2004 Sep;75(3):504-7.Full text Abstract
24. Wang JM, Xu WD, Huang AF. Association of STAT4 gene Rs7574865, Rs10168266 polymorphisms and systemic lupus erythematosus susceptibility: a meta-analysis. 2021 Feb;50(2-3):282-94. Abstract
25. D'Cruz DP, Khamashta MA, Hughes GRV. Systemic lupus erythematosus. Lancet. 2007 Feb 17;369(9561):587-96. Abstract
26. Jiang F, Li S, Jia C. Smoking and the risk of systemic lupus erythematosus: an updated systematic review and cumulative meta-analysis. Clin Rheumatol. 2015 Nov;34(11):1885-92. Abstract
27. Parisis D, Bernier C, Chasset F, et al. Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2019 Nov;18(11):102393. Abstract
28. Harel-Meir M. Sherer Y, Shoenfeld Y. Tobacco smoking and autoimmune disease. Nat Clin Pract Rheumatol. 2007 Dec;3(12):707-15. Abstract
29. Montes RA, Mocarzel LO, Lanzieri PG, et al. Smoking and its association with morbidity in systemic lupus erythematosus evaluated by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index: preliminary data and systematic review. Arthritis Rheumatol. 2016 Feb;68(2):441-8.Full text Abstract
30. Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am. 1994 Feb;20(1):61-86. Abstract
31. Haugaard JH, Kofoed K, Gislason G, et al. Association between drug use and subsequent diagnosis of lupus erythematosus. JAMA Dermatol. 2020 Nov 1;156(11):1199-207.Full text Abstract
32. Blomgren SE, Condemi JJ, Vaughan JH. Procainamide-induced lupus erythematosus: clinical and laboratory observations. Am J Med. 1972 Mar;52(3):338-48. Abstract
33. Sclienger RG, Bircher AJ, Meier CR. Minocycline-induced lupus: a systematic review. Dermatology. 2000;200(3):223-31. Abstract
34. Gordon MM, Porter D. Minocycline induced lupus: case series in the West of Scotland. J Rheumatol. 2001 May;28(5):1004-6. Abstract
35. McKellar G, Porter D, Burden D. Terbinafine as a cause of cutaneous lupus erythematosus. Rheumatology (Oxford). 2004 Feb;43(2):249. Abstract
36. Gunnarsson I, Nordmark B, Hassan Bakri A et al. Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA. Rheumatology (Oxford). 2000 Aug;39(8):886-93.Full text Abstract
37. Siddiqui MA, Khan IA. Isoniazid-induced lupus erythematosus presenting with cardiac tamponade. Am J Ther. 2002 Mar-Apr;9(2):163-5. Abstract
38. Scheinfeld N. Impact of phenytoin therapy on the skin and skin disease. Expert Opin Drug Saf. 2004 Nov;3(6):655-65. Abstract
39. Pelizza L, De Luca P, La Pesa M, et al. Drug-induced systemic lupus erythematosus after 7 years of treatment with carbamazepine. Acta Biomed. 2006 Apr;77(1):17-9. Abstract
40. Rezayat AA, Niloufar Jafari, Mir Nourbakhsh SH, et al. The effect of air pollution on systemic lupus erythematosus: a systematic review and meta-analysis. Lupus. 2022 Nov;31(13):1606-18. Abstract
41. Morotti A, Sollaku I, Catalani S, et al. Systematic review and meta-analysis of epidemiological studies on the association of occupational exposure to free crystalline silica and systemic lupus erythematosus. Rheumatology (Oxford). 2021 Jan 5;60(1):81-91. Abstract
42. Illescas-Montes R, Corona-Castro CC, Melguizo-Rodríguez L, et al. Infectious processes and systemic lupus erythematosus. Immunology. 2019 Nov;158(3):153-60.Full text Abstract
43. Li ZX, Zeng S, Wu HX, et al. The risk of systemic lupus erythematosus associated with Epstein-Barr virus infection: a systematic review and meta-analysis. Clin Exp Med. 2019 Feb;19(1):23-36.Full text Abstract
44. Hanlon P, Avenell A, Aucott L, et al. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Arthritis Res Ther. 2014 Jan 6;16(1):R3.Full text Abstract
45. Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol. 2015 Jun;11(6):329-41. Abstract
46. Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol. 2013 Sep;24(9):1357-66.Full text Abstract
47. Postal M, Vivaldo JF, Fernandez-Ruiz R, et al. Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr Opin Immunol. 2020 Dec;67:87-94.Full text Abstract
48. Crow MK. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann Rheum Dis. 2023 Aug;82(8):999-1014.Full text Abstract
49. Frangou E, Vassilopoulos D, Boletis J, et al. An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): Implications for the pathogenesis and treatment. Autoimmun Rev. 2019 Aug;18(8):751-60. Abstract
50. Boodhoo KD, Liu S, Zuo X. Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Medicine (Baltimore). 2016 Jul;95(29):e4272.Full text Abstract
51. Chua MHY, Ng IAT, W L-Cheung M, et al. Association between cigarette smoking and systemic lupus erythematosus: an updated multivariate Bayesian metaanalysis. J Rheumatol. 2020 Oct 1;47(10):1514-21.Full text Abstract
52. Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun. 2019 Jan;96:1-13. Abstract
53. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024 Jan 2;83(1):15-29.Full text Abstract
54. van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017 Mar;76(3):554-61. Abstract
55. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014 Jun;73(6):958-67. Abstract
56. McKinley PS, Ouellette SC, Winkel GH. The contributions of disease activity, sleep patterns and depression to fatigue in SLE: a proposed model. Arthritis Rheum. 1995 Jun;38(6):826-34. Abstract
57. Leuchten N, Milke B, Winkler-Rohlfing B, et al. Early symptoms of systemic lupus erythematosus (SLE) recalled by 339 SLE patients. Lupus. 2018 Aug;27(9):1431-6. Abstract
58. Zandman-Goddard G, Schoenfeld Y. SLE and infections. Clin Rev Allergy Immunol. 2003 Aug;25(1):29-40. Abstract
59. García-Ríos P, Pecci-Lloret MP, Oñate-Sánchez RE. Oral manifestations of systemic lupus erythematosus: a systematic review. Int J Environ Res Public Health. 2022 Sep 21;19(19):11910.Full text Abstract
60. Du F, Qian W, Zhang X, et al. Prevalence of oral mucosal lesions in patients with systemic lupus erythematosus: a systematic review and meta-analysis. BMC Oral Health. 2023 Dec 21;23(1):1030.Full text Abstract
61. Vitali C, Doria A, Tincani A. International survey on the management of patients with SLE. I. General data on the participating centers and the results of a questionnaire regarding mucocutaneous involvement. Clin Exp Rheumatol. 1996 Nov-Dec;14(suppl 16):S17-22. Abstract
62. Dubois EL, Tuffanelli DL. Clinical manifestations of SLE: computer analysis of 520 cases. JAMA. 1964 Oct 12;190:104-11. Abstract
63. Hochberg MC, Boyd RE, Ahearn JM, et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine (Baltimore). 1985 Sep;64(5):285-95. Abstract
64. Sarwar S, Mohamed AS, Rogers S, et al. Neuropsychiatric systemic lupus erythematosus: a 2021 update on diagnosis, management, and current challenges. Cureus. 2021 Sep;13(9):e17969.Full text Abstract
65. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999 Apr;42(4):599-608. Abstract
66. Santacruz JC, Mantilla MJ, Rueda I, et al. A practical perspective of the hematologic manifestations of systemic lupus erythematosus. Cureus. 2022 Mar;14(3):e22938.Full text Abstract
67. Zagelbaum Ward NK, Linares-Koloffon C, Posligua A, et al. Cardiac manifestations of systemic lupus erythematous: an overview of the incidence, risk factors, diagnostic criteria, pathophysiology and treatment options. Cardiol Rev. 2022 Jan-Feb 01;30(1):38-43. Abstract
68. Memet B, Ginzler EM. Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med. 2007 Aug;28(4):441-50. Abstract
69. Man BL, Mok CC. Serositis related to systemic lupus erythematosus: prevalence and outcome. Lupus. 2005;14(10):822-6. Abstract
70. Kim YJ, Lovell J, Diab A, et al. Incidence and factors associated with recurrent pericarditis in lupus. JAMA Netw Open. 2025 Feb 3;8(2):e2461610.Full text Abstract
71. Gu MM, Wang XP, Cheng QY, et al. A meta-analysis of cardiovascular events in systemic lupus erythematosus. Immunol Invest. 2019 Jul;48(5):505-20. Abstract
72. Li H, Tong Q, Guo L, et al. Risk of coronary artery disease in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Am J Med Sci. 2018 Nov;356(5):451-63. Abstract
73. Yazdany J, Pooley N, Langham J, et al. Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis. RMD Open. 2020 Sep;6(2):e001247.Full text Abstract
74. Lu X, Wang Y, Zhang J, et al. Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: a systematic review and meta-analysis. Int Immunopharmacol. 2021 May;94:107466. Abstract
75. Bello N, Meyers KJ, Workman J, et al. Cardiovascular events and risk in patients with systemic lupus erythematosus: systematic literature review and meta-analysis. Lupus. 2023 Mar;32(3):325-41.Full text Abstract
76. Di Minno MND, Forte F, Tufano A, et al. Speckle tracking echocardiography in patients with systemic lupus erythematosus: a meta-analysis. Eur J Intern Med. 2020 Mar;73:16-22. Abstract
77. Duron L, Cohen-Aubart F, Diot E, et al. Shrinking lung syndrome associated with systemic lupus erythematosus: a multicenter collaborative study of 15 new cases and a review of the 155 cases in the literature focusing on treatment response and long-term outcomes. Autoimmun Rev. 2016 Oct;15(10):994-1000. Abstract
78. Leone P, Prete M, Malerba E, et al. Lupus vasculitis: an overview. Biomedicines. 2021 Nov 5;9(11):1626.Full text Abstract
79. Hallegua DS, Wallace DJ. Gastrointestinal manifestations of systemic lupus erythematosus. Curr Opin Rheumatol. 2000 Sep;12(5):379-85. Abstract
80. Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis. 2010 Aug;69(8):1420-2. Abstract
81. American College of Rheumatology. Methodology of testing for antinuclear antibodies. 2019 [internet publication].Full text
82. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997 Sep;40(9):1601-11. Abstract
83. Smeenk R, Brinkman K, van den Brink H, et al. Antibodies to DNA in patients with systemic lupus erythematosus: their role in the diagnosis, the follow-up and the pathogenesis of the disease. Clin Rheumatol. 1990 Mar;9(1 suppl 1):100-10. Abstract
84. Eaton RB, Schnneider G, Schur PH. Enzyme immunoassay for antibodies to native DNA. Specificity and quality of antibodies. Arthritis Rheum. 1983 Jan;26(1):52-62. Abstract
85. Arachchillage DJ, Platton S, Hickey K, et al. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2024 Sep;205(3):855-80.Full text Abstract
86. Sammaritano LR, Askanase A, Bermas BL, et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Rheumatol. 2025 Sep;77(9):1115-35.Full text Abstract
87. Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024 Jan;105(1s):S1-69.Full text Abstract
88. Choi MY, FitzPatrick RD, Buhler K, et al. A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus. Autoimmun Rev. 2020 Mar;19(3):102463.Full text Abstract
89. Ho RC, Thiaghu C, Ong H, et al. A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. Autoimmun Rev. 2016 Feb;15(2):124-38. Abstract
90. Buleu F, Sirbu E, Caraba A, et al. Heart involvement in inflammatory rheumatic diseases: a systematic literature review. Medicina (Kaunas). 2019 Jun 6;55(6):249.Full text Abstract
91. Simundic AM, Bölenius K, Cadamuro J, et al. Joint EFLM-COLABIOCLI recommendation for venous blood sampling. Clin Chem Lab Med 2018;56(12):2015-38. Abstract
92. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002 Apr;46(4):1019-27. Abstract
93. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the anti-phospholipid syndrome. Blood. 2007 Jan 15;109(2):422-30.Full text Abstract
94. Drosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022 Jun;81(6):768-79.Full text Abstract
95. Parodis I, Girard-Guyonvarc'h C, Arnaud L, et al. EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. Ann Rheum Dis. 2024 May 15;83(6):720-9.Full text Abstract
96. Lehmann P, Homey B. Clinic and pathophysiology of photosensitivity in lupus erythematosus. Autoimmun Rev. 2009 May;8(6):456-61. Abstract
97. Kuhn A, Gensch K, Haust M, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol. 2011 Jan;64(1):37-48.Full text Abstract
98. Chasset F, Francès C, Barete S, et al. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol. 2015 Apr;72(4):634-9. Abstract
99. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol. 2000 Jun;42(6):983-7. Abstract
100. Rodríguez Huerta MD, Trujillo-Martín MM, Rúa-Figueroa Í, et al. Healthy lifestyle habits for patients with systemic lupus erythematosus: a systemic review. Semin Arthritis Rheum. 2016 Feb;45(4):463-70. Abstract
101. Wang XR, Xiao JP, Zhang JJ, el. Decreased serum/plasma vitamin D levels in SLE patients: a meta-analysis. Curr Pharm Des. 2018;24(37):4466-73. Abstract
102. Islam MA, Khandker SS, Alam SS, et al. Vitamin D status in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Autoimmun Rev. 2019 Nov;18(11):102392. Abstract
103. Sousa JR, Cunha Rosa EP, Costa Nunes IF, et al. Effect of vitamin D supplementation on patients with systemic lupus erythematosus: a systematic review. Rev Bras Reumatol Engl Ed. Sep-Oct 2017;57(5):466-71.Full text Abstract
104. de Medeiros MCS, Medeiros JCA, de Medeiros HJ, et al. Dietary intervention and health in patients with systemic lupus erythematosus: a systematic review of the evidence. Crit Rev Food Sci Nutr. 2019;59(16):2666-73. Abstract
105. Zheng R, Gonzalez A, Yue J, et al. Efficacy and safety of vitamin D supplementation in patients with systemic lupus erythematosus: a meta-analysis of randomized controlled trials. Am J Med Sci. 2019 Aug;358(2):104-14. Abstract
106. Jiao H, Acar G, Robinson GA, et al. Diet and systemic lupus erythematosus (SLE): from supplementation to intervention. Int J Environ Res Public Health. 2022 Sep 20;19(19):11895.Full text Abstract
107. Duarte-García A, Myasoedova E, Karmacharya P, et al. Effect of omega-3 fatty acids on systemic lupus erythematosus disease activity: a systematic review and meta-analysis. Autoimmun Rev. 2020 Dec;19(12):102688. Abstract
108. Ramessar N, Borad A, Schlesinger N. The effect of omega-3 fatty acid supplementation in systemic lupus erythematosus patients: a systematic review. Lupus. 2022 Mar;31(3):287-96. Abstract
109. Blaess J, Goepfert T, Geneton S, et al. Benefits & risks of physical activity in patients with systemic lupus erythematosus: a systematic review of the literature. Semin Arthritis Rheum. 2023 Feb;58:152128. Abstract
110. Gu M, Cheng Q, Wang X, et al. The impact of SLE on health-related quality of life assessed with SF-36: a systemic review and meta-analysis. Lupus. 2019 Mar;28(3):371-82. Abstract
111. Li Z, Yang Y, Dong C, et al. The prevalence of suicidal ideation and suicide attempt in patients with rheumatic diseases: a systematic review and meta-analysis. Psychol Health Med. 2018 Oct;23(9):1025-36. Abstract
112. Fangtham M, Kasturi S, Bannuru RR, et al. Non-pharmacologic therapies for systemic lupus erythematosus. Lupus. 2019 May;28(6):703-12.Full text Abstract
113. Poole JL, Bradford JD, Siegel P. Effectiveness of occupational therapy interventions for adults with systemic lupus erythematosus: a systematic review. Am J Occup Ther. 2019 Jul/Aug;73(4). Abstract
114. Bruce IN, Mak VC, Hallett DC, et al. Factors associated with fatigue in patients with systemic lupus erythematosus. Ann Rheum Dis. 1999 Jun;58(6):379-81.Full text Abstract
115. Zonana-Nacach A, Roseman JM, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups, VI: factors associated with fatigue within five year of criteria diagnosis. Lupus. 2000;9(2):101-9. Abstract
116. Zhao Q, Deng N, Chen S, et al. Systemic lupus erythematosus is associated with negatively variable impacts on domains of sleep disturbances: a systematic review and meta-analysis. Psychol Health Med. 2018 Jul;23(6):685-97. Abstract
117. Yin R, Li L, Xu L, et al. Association between depression and sleep quality in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Sleep Breath. 2022 Mar;26(1):429-41.Full text Abstract
118. Wu L, Shi PL, Tao SS, et al. Decreased sleep quality in patients with systemic lupus erythematosus: a meta-analysis. Clin Rheumatol. 2021 Mar;40(3):913-22. Abstract
119. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003 Sep;82(5):299-308.Full text Abstract
120. Cojocaru M, Cojocaru IM, Silosi I, et al. Manifestations of systemic lupus erythematosus. Maedica (Bucur). 2011 Oct;6(4):330-6.Full text Abstract
121. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010 Jan;69(1):20-8. Abstract
122. Cai T, Zhao J, Yang Y, et al. Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: a systematic review and meta-analysis of cohort studies. Lupus. 2022 Dec;31(14):1714-25. Abstract
123. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014 Dec;132(12):1453-60.Full text Abstract
124. Kim JW, Kim YY, Lee H, et al. Risk of retinal toxicity in longterm users of hydroxychloroquine. J Rheumatol. 2017 Nov;44(11):1674-9.Full text Abstract
125. Ugarte-Gil MF, Mak A, Leong J, et al. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci Med. 2021 Dec;8(1):e000590.Full text Abstract
126. Sun T, Wang J, Zhang R, et al. A systematic review and meta-analysis: effects of glucocorticoids on rheumatoid arthritis and systemic lupus erythematosus. Ann Palliat Med. 2021 Jul;10(7):7977-91.Full text Abstract
127. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Feb 26;377(9767):721-31. Abstract
128. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15;61(9):1168-78.Full text Abstract
129. Wallace DJ, Ginzler EM, Merrill JT, et al. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2019 Jul;71(7):1125-34.Full text Abstract
130. Iwata S, Saito K, Hirata S, et al. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus. 2018 Apr;27(5):802-11. Abstract
131. National Institute for Health and Care Excellence. Belimumab for treating active autoantibody-positive systemic lupus erythematosus. Technology appraisal guidance [TA752]. Dec 2021 [internet publication].Full text
132. Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Feb 25;2(2):CD010668.Full text Abstract
133. Urowitz MB, Ohsfeldt RL, Wielage RC, et al. Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. Ann Rheum Dis. 2019 Mar;78(3):372-9.Full text Abstract
134. Xu Y, Xu JW, Wang YJ, et al. Belimumab combined with standard therapy does not increase adverse effects compared with a control treatment: a systematic review and meta-analysis of randomised controlled trials. Int Immunopharmacol. 2022 Aug;109:108811. Abstract
135. ClinicalTrials.gov. Efficacy and safety of two doses of anifrolumab compared to placebo in adult subjects with active systemic lupus erythematosus. December 2019 [internet publication].Full text
136. Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020 Jan 16;382(3):211-21.Full text Abstract
137. Kalunian KC, Furie R, Morand EF, et al. A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol. 2023 Feb;75(2):253-65.Full text Abstract
138. Liu Z, Cheng R, Liu Y. Evaluation of anifrolumab safety in systemic lupus erythematosus: a meta-analysis and systematic review. Front Immunol. 2022;13:996662.Full text Abstract
139. Palmowski A, Pankow A, Terziyska K, et al. Continuing versus tapering low-dose glucocorticoids in patients with rheumatoid arthritis and systemic lupus erythematosus in states of low disease activity or remission: a systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum. 2024 Feb;64:152349. Abstract
140. Ji L, Xie W, Zhang Z. Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual. Rheumatology (Oxford). 2021 Dec 1;60(12):5517-26.Full text Abstract
141. William HJ, Egger MJ, Singer JZ, et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol. 1994 Aug;21(8):1457-62. Abstract
142. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991 Jan 17;324(3):150-4.Full text Abstract
143. Rodríguez SC, Olguín AM, Miralles CP, et al. Characteristics of meningitis caused by ibuprofen: report of 2 cases with recurrent episodes and review of the literature. Medicine (Baltimore). 2006 Jul;85(4):214-20. Abstract
144. Hoffman M, Gray RG. Ibuprofen-induced meningitis in mixed connective tissue disease. Clin Rheumatol. 1982 Jun;1(2):128-30. Abstract
145. Wasner CK. Ibuprofen, meningitis, and systemic lupus erythematosus. J Rheumatol. Summer 1978;5(2):162-4. Abstract
146. O'Kane D, McCourt C, Meggitt S, et al. British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021. Br J Dermatol. 2021 Dec;185(6):1112-23.Full text Abstract
147. Lupus UK. The mouth and lupus [internet publication].Full text
148. Altenburg A, El-Haj N, Micheli C, et al. The treatment of chronic recurrent oral aphthous ulcers. Dtsch Arztebl Int. 2014 Oct 3;111(40):665-73.Full text Abstract
149. Wang L, Xie Y, Deng Y. Prevalence of dry eye in patients with systemic lupus erythematosus: a meta-analysis. BMJ Open. 2021 Sep 29;11(9):e047081. Abstract
150. Magro-Checa C, Zirkzee EJ, Huizinga TW, et al. Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives. Drugs. 2016 Mar;76(4):459-83.Full text Abstract
151. Lee YH, Song GG. Multitarget therapy versus monotherapy as induction treatment for lupus nephritis: a meta-analysis of randomized controlled trials. Lupus. 2022 Oct;31(12):1468-76. Abstract
152. Kasitanon N, Fine DM, Haas M, et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus. 2006;15(6):366-70. Abstract
153. National Institute for Health and Care Excellence. Voclosporin with mycophenolate mofetil for treating lupus nephritis. May 2023 [internet publication].Full text
154. Jiang YP, Zhao XX, Chen RR, et al. Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: a systematic review and meta-analysis. Medicine (Baltimore). 2020 Sep 18;99(38):e22328.Full text Abstract
155. Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020 Sep 17;383(12):1117-28.Full text Abstract
156. Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021 May 29;397(10289):2070-80. Abstract
157. Saxena A, Ginzler EM, Gibson K, et al. Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial. Arthritis Rheumatol. 2024 Jan;76(1):59-67.Full text Abstract
158. Carneiro JR, Sato EI. Double-blind, randomised, placebo controlled trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999 Jun;26(6):1275-9. Abstract
159. Lee YH, Bae SC. Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Z Rheumatol. 2018 May;77(4):335-42. Abstract
160. Emery P, Blanco R, Maldonado Cocco J, et al. Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. RMD Open. 2017 Mar 21;3(1):e000410.Full text Abstract
161. Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016 Mar 31;374(13):1243-52.Full text Abstract
162. Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017 Jan;76(1):88-95.Full text Abstract
163. Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018 Jul 21;392(10143):222-31. Abstract
164. Morand EF, Vital EM, Petri M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 2023 Mar 25;401(10381):1001-10. Abstract
165. Petri M, Bruce IN, Dörner T, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet. 2023 Mar 25;401(10381):1011-19. Abstract
166. ClinicalTrials.gov. A study to evaluate the safety and efficacy of obinutuzumab compared with placebo in participants with lupus nephritis (LN). November 2021 [internet publication].Full text
167. Furie R, Aroca G, Alvarez A, et al. Two-year results from a randomized, controlled study of obinutuzumab for proliferative lupus nephritis. Abstract number 0988: ACR Convergence 2020. Arthritis Rheumatol. 2020; 72 (suppl 10).Full text
168. ClinicalTrials.gov. Study of EQ001 (itolizumab) in systemic lupus erythematosus with or without active proliferative nephritis (EQUALISE). November 2021 [internet publication].Full text
169. Merrill JT, Shanahan WR, Scheinberg M, et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 Jun;77(6):883-9.Full text Abstract
170. ClinicalTrials.gov. RESET-SLE: a phase 1/2 open-label study to evaluate the safety and efficacy of CABA-201 in subjects with active systemic lupus erythematosus. Oct 2025 [internet publication].Full text
171. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5 year period. A multicentre prospective study of 1000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1999 May;78(3):167-75. Abstract
172. Cervera R, Abarca-Costalago M, Abramovicz D, et al. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". AAutoimmun Rev. 2006 Mar;5(3):180-6. Abstract
173. Lee YH, Choi SJ, Ji JD, et al. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016 Jun;25(7):727-34. Abstract
174. Fors Nieves CE, Izmirly PM. Mortality in systemic lupus erythematosus: an updated review. Curr Rheumatol Rep. 2016 Apr;18(4):21. Abstract
175. Murimi-Worstell IB, Lin DH, Nab H, et al. Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis. BMJ Open. 2020 May 21;10(5):e031850.Full text Abstract
176. Yang J, Zhou F, Zhou X, et al. Survival and prognosis analysis of systemic lupus erythematosus patients with pulmonary hypertension: a systematic review and meta-analysis. Medicine (Baltimore). 2023 Sep 8;102(36):e34947.Full text Abstract
177. Qian J, Wang Y, Huang C, et al. Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: a PRISMA-compliant systematic review and meta-analysis. Autoimmun Rev. 2016 Mar;15(3):250-7. Abstract
178. Asenjo-Lobos C, González L, Bulnes JF, et al. Cardiovascular events risk in patients with systemic autoimmune diseases: a prognostic systematic review and meta-analysis. Clin Res Cardiol. 2024 Feb;113(2):246-59. Abstract
179. Ballocca F, D'Ascenzo F, Moretti C, et al. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol. 2015 Nov;22(11):1435-41.Full text Abstract
180. Bernatsky S, Joseph L, Boivin JF, et al. The relationship between cancer and medication exposures in systemic lupus erythematosus: a case-cohort study. Ann Rheum Dis. 2008 Jan;67(1):74-9. Abstract
181. Schneider V, Levesque LE, Zhang B, et al. Association of selective and conventional non-steroidal anti inflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006 Nov 1;164(9):881-9.Full text Abstract
182. Breuer GS, Baer A, Dahan D, Nesher G. Lupus-associated pancreatitis. Autoimmun Rev. 2006 May;5(5):314-8. Abstract
183. Nesher G, Breuer GS, Temprano K, et al. Lupus-associated pancreatitis. Semin Arthritis Rheum. 2006 Feb;35(4):260-7. Abstract
184. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995 Apr 13;332(15):993-7.Full text Abstract
185. Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus. 2004;13(9):673-8. Abstract
186. Manger K, Wildt L, Kalden JR, et al. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev. 2006 Apr;5(4):269-72. Abstract
187. Soares PM, Borba EF, Bonfa E, et al. Gonad evaluation in male systemic lupus erythematosus. Arthritis Rheum. 2007 Jul;56(7):2352-61.Full text Abstract
188. Hussain K, Gauto-Mariotti E, Cattoni HM, et al. A meta-analysis and systematic review of valvular heart disease in systemic lupus erythematosus and its association with antiphospholipid antibodies. J Clin Rheumatol. 2021 Dec 1;27(8):e525-32. Abstract
189. Oshiro BT, Silver RM, Scott JR, et al. Antiphospholipid antibodies and fetal death. Obstet Gynecol. 1996 Apr;87(4):489-93. Abstract
190. Out HJ, Bruinse HW, Christiaens GC, et al. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol. 1992 Jul;167(1):26-32. Abstract
191. Kozora E, Ellison MC, West S. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis Rheum. 2006 Aug 15;55(4):628-35.Full text Abstract
192. Jiang M, Chen R, Zhao L, et al. Risk factors for mortality of diffuse alveolar hemorrhage in systemic lupus erythematosus: a systematic review and meta-analysis. Arthritis Res Ther. 2021 Feb 16;23(1):57.Full text Abstract
193. Wang X, Yan S, Liu C, et al. Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Osteoporos Int. 2016 Apr;27(4):1413-23. Abstract
194. Henegar CE, Eudy AM, Kharat V, et al. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. Lupus. 2016 May;25(6):617-26. Abstract
195. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptive in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2550-8.Full text Abstract
196. Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2539-49.Full text Abstract
197. Clowse ME, Magder L, Whitter F, et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006 Nov;54(11):3640-7.Full text Abstract
198. Battafarano DF, Battafarano NJ, Larsen L et al. Antigen specific antibody responses in lupus patients following immunization. Arthritis Rheum. 1998 Oct;41(10):1828-34. Abstract
199. Holvast A, Huckriede A, Wilschut J, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis. 2006 Jul;65(7):913-8.Full text Abstract
200. Mathian A, Pha M, Amoura Z. Lupus and vaccinations. Curr Opin Rheumatol. 2018 Sep;30(5):465-70. Abstract
201. Huang Y, Wang H, Wan L, et al. Is systemic lupus erythematosus associated with a declined immunogenicity and poor safety of influenza vaccination? A systematic review and meta-analysis. Medicine (Baltimore). 2016 May;95(19):e3637.Full text Abstract
Use of this content is subject to our disclaimer